Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Sanofi-a Ventis Deutschland Gmbh

Rhone-poulenc Sante

Koranex Capital

Novexel

Novexel Sa

Serge Mignani

Jean-Christophe Carry

Patrick Jimonet

Jean-Luc Malleron

Michel Evers

Jean-Claude Aloup

Arielle Genevois-Borella

Dominique Damour

Michel Tabart

Antony Bigot

Jean Bouquerel

Baptiste Ronan

Bruno Filoche

Georges Bashiardes

Fabrice Viviani

Jean-Claude Hardy

Patrick Nemecek

Yves Ribeill

Francedillaois Audiau

Eric Bacque

Michel Barreau

Claude Gueremy

Heinz-Werner Kleemann

Francois Audiau

Youssef El-Ahmad

Youssef El Ahmad

Jean-Claude Barriere

Franco Manfre

Pascal Desmazeau

Jean-Fran&ccedil;ois Peyronel

Claude Guyon

Michel Cheve

Gilles Doerflinger

Guy Pantel

Marc Capet

Armin Hofmeister

Jean-Francois Peyronel

Daniel Achard

Augustin Hittinger

Jean-Paul Martin

Serge Moffett

Alain Truchon

Jean-Francois Sabuco

Andrees Bohme

Philippe Hubert

Eric Bacqué

Gaetan Touyer

Rene Roy

Tze Chieh Shiao

St&eacute;phane Mutti

Corrine Terrier

Serg Grisoni

Christophe Daubi&eacute;

Eric Bacqu&eacute;

Laurent Schio

Bruno Filoche-Romme

Hervé Bouchard

Jacques Mauger

Conception Nemecek

Herv&eacute; Bouchard

Anil Nair

Francois Clerc

Hervé Minoux

Pascal Billot

Erik Louvel

Marie-Therese Comte

Kirsten Bjergarde

Cecile Combeau

Jean-Pierre Leconte

Odile Angouillant-Boniface

Carole Neves

Alain Le Brun

Richard Labaudiniere

Jean-Christophe Gueguen

Michel Martinet

Jacques Bourget

Marc Antoine Perrin

Bernd Janocha

Sylvaine Lafont

Eric Baque

Marie-Iherese Comte

Claude Gaillard

Philip Chapelle

Gerard Sanderink

Nina Ma

Claude Bensoussan

Jean Bououerel

Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

Neoglycoconjugates as vaccines and therapeutic tools

This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH, ORc, SRc, SORa, SORa, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSORa, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF, CHF, CHF, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them

The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.

3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them

The present invention relates to the novel isoindolone derivatives of the formula I in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.

Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them

The present invention relates to the novel derivatives of formula (I) in which  A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH, ORc, SRc, SORa, SORa, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSORa, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF, CHF, CHF, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.

The invention relates to 4-substituted quinoline compounds of general formula: which are active as antimicrobials, in which:

4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them

Quinolylpropylpiperidine derivatives of general formula (I) in which Ris hydrogen or fluorine, Ris carboxyl, carboxymethyl or hydroxymethyl, Ris alkyl substituted either with phenylthio optionally substituted with halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano or amino, or with cycloalkylthio (3 to 7 members) optionally substituted with halogen or trifluoromethyl, or with heteroarylthio (5 to 6 members and 1 to 4 heteroatoms chosen from N, O and S), optionally substituted with halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano or amino or Ris propargyl substituted by phenyl or heteroaryl as defined above and Ris alkyl, alkenyl-CH&#x2014; or alkynyl-CH&#x2014;, cycloalkyl or cycloalkylalkyl, in their various isomeric forms, separate or as mixtures, and also their salts, their preparation process and intermediates and the compositions containing them. These novel derivatives are potent antibacterial agents 

Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor

The present invention discloses and claims compounds of formula I and their pharmaceutically acceptable salts, and methods of using said compounds of formula I, either alone or in combination with other medicaments, as antiarrhythmic medicaments with a cardioprotective component for prophylaxis or treatment of infarction, for the treatment of angina pectoris, and as inhibitors of pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure. Pharmaceutical compositions comprising compounds of formula I or compounds of formula I in combination with one or more other medicaments and processes for the preparation of compounds of formula I are also disclosed and claimed.

Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom

The present invention relates to a process for preparing 2-amino-thiazoline derivatives of formula (II): in which either Y is a methylene (CH) and X is chosen from the following groups: O, NH, (C1&#x2013;C4) N-Alkyl, N-Bn, N-Ph, N-(2-Py), N-(3-Py), N-(4-Py), N-2-pyrimidyl, N-5-pyrimidyl, S, SO, SO, CHor CHPh; or Y is a carbonyl (C&#x2550;O) and X is chosen from the following groups: NH, N-Ph, N-(2-Py), N-(3-Py), N-(4-Py), N-2-pyrimidyl or N-5-pyrimidyl.

Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase

The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-pyrrole derivatives of formula (I) wherein Rto Rand Ar are as defined herein, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation 

Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them

The present invention relates to the novel isoindolone derivatives of the formula Iin which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.

The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure:and as characterized herein by powder X-ray diffraction patterns as form A and form B, processes for preparing form A from the purified amorphous form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a processes for preparing form A by heating monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a pharmaceutical composition comprising form A, a pharmaceutical composition comprising form A and form B or monohydrated form C, a pharmaceutical composition comprising form A, form B and monohydrated form C, a method for treating a bacterial infection with form A, a method for treating a bacterial infection with form A and form B or monohydrated form C, and a method for treating a bacterial infection with form A and form B and monohydrated form C.

Crystalline form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperindine-3-carboxylic acid

Growing community of inventors

Chatenay-Malabry, France

Serge Mignani